Tissue protective and anti-fibrotic actions of suramin: New uses of an old drug

Current Clinical Pharmacology

Volumn 6, Issue 2, 2011, Pages 137-142

  Liu, Na ^a,b   Zhuang, Shougang ^a  

^a BROWN UNIVERSITY   (United States)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Anti fibrosis; Myofibroblast; Proliferation; Suramin; Tissue protection

Indexed keywords

CARBOPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL; SURAMIN;

ADRENAL DISEASE; ANEMIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONJUNCTIVITIS; DRUG MECHANISM; ELECTROLYTE DISTURBANCE; EYELID EDEMA; FATIGUE; GLAUCOMA; HEART PROTECTION; HEMOLYTIC ANEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; KERATOPATHY; LIVER PROTECTION; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; NAUSEA; NEUROPROTECTION; NEUTROPENIA; NONHUMAN; PAPULAR RASH; PHARMACODYNAMICS; PHOTOPHOBIA; PRIORITY JOURNAL; PRURITUS; RASH; RENAL PROTECTION; REVIEW; SKELETAL MUSCLE; STOMATITIS; THROMBOCYTOPENIA; URTICARIA; VOMITING; VORTEX KERATOPATHY; WOUND HEALING;

APOPTOSIS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY; LIVER CIRRHOSIS; MUSCLE, SKELETAL; NEUROPROTECTIVE AGENTS; SURAMIN; WOUND HEALING;

EID: 79959333259     PISSN: 15748847     EISSN: 15748847     Source Type: Journal    
DOI: 10.2174/157488411796151174     Document Type: Review

References (70)

1. McGeary RP, Bennett AJ, Tran QB, Cosgrove KL, Ross BP. Suramin: clinical uses and structure-activity relationships. Mini Rev Med Chem 2008; 8: 1384-94.
2. Steverding D. The development of drugs for treatment of sleeping sickness: a historical review. Parasit Vectors 2010; 3: 15.
3. Schlitzer M. [Agents for the treatment of African sleeping sickness. Those developed in the last century]. Pharm Unserer Zeit 2009; 38: 552-8.
4. Voogd TE, Vansterkenburg EL, Wilting J. Janssen LH. Recent research onthe biological activity of suramin. Pharmacol 1993; 45: 177-203.
5. Korten SBM, Büttner DW, Hoerauf A, Brattig N, Fleischer B. Natural death of adult Onchocerca volvulus and filaricidal effects of doxycycline induce local FOXP3+/CD4+ regulatory T cells and granzyme expression. Microbes Infect 2008; 10: 313-24.
6. Erguven M, Akev N, Ozdemir A, Karabulut E, Bilir A. The inhibitory effect of suramin on telomerase activity and spheroid growth of C6 glioma cells. Med Sci Monit 2008; 14: 165-73.
7. Kolmakova A, Rajesh M, Zang D, Pili R, Chatterjee S. VEGF recruits lactosylceramide to induce endothelial cell adhesion molecule expression and angiogenesis in vitro and in vivo. Glycoconj J 2009; 26: 547-58.
8. Small EJ, Meyer M, Marshall ME, et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000; 18: 1440-50.
9. Eisenberger MASV, Reyno L. Suramin. Cancer Pract 1995; 3.
10. Allolio B, Jaursch-Hancke C, Reincke M, Arlt W, Metzler U, Winkelmann W. Treatment of metastatic adrenal carcinoma with suramin. Dtsch Med Wochenschr. 1989; 114: 381-4.
11. La Rocca RV, Stein CA, Myers CE. Suramin: prototype of a new generation of antitumor compounds. Cancer Cells 1990; 2: 106-15.
12. Shin R, Naomoto Y, Kamikawa Y, Tanaka N, Orita K. Effect of suramin on human esophageal cancer cells in vitro and in vivo. Scand J Gastroenterol. 1997; 32: 824-28.
13. Schuetz A, Min J, Antoshenko T, et al. Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin. Structure 2007; 15: 377-89.
14. Song S, Yu B, Wei Y, Wientjes MG, Au JL Low-dose,suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxelpretreated human breast xenograft tumors. Clin Cancer Res 2004; 10: 6058-65.
15. Stein CA, LaRocca RV, Thomas R, McAtee N, Myers CE. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 1989; 7: 499-508.
16. Lee HS, Chung SK. The effect of subconjunctival suramin on corneal neovascularization in rabbits. Cornea 2010; 29: 86-92.
17. McCain DF, Wu L, Nickel P, et al. Suramin derivatives as inhibitors and activators of protein-tyrosine phosphatases. J Biol Chem 2004; 279: 14713-25.
18. Trapp J, Meier R, Hongwiset D, Kassack MU, Sippl W, Jung M. Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins). Chem Med Chem 2007; 2: 1419-31.
19. Bocci G, Danesi R, Benelli U, et al. Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. Cancer Chemother Pharmacol 1999; 43: 829-37.
20. Kassack MU, Braun K, Ganso M, et al. Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur J Med Chem 2004; 39: 345-57.
21. Carlström M WP, Skøtt O, Persson AE, Eriksson UJJ Hypertens. Angiogenesis inhibition causes hypertension and placental dysfunction in a rat model of preeclampsia. J Hypertens 2009; 27: 829-37.
22. Guns PJ, Hendrickx J, Van Assche T, Fransen P, Bult H. P2Y receptors and atherosclerosis in apolipoprotein E-deficient mice. Br J Pharmacol 2010; 159: 326-36.
23. Kathir KM, Kumar TK, Yu C. Understanding the mechanism of the antimitogenic activity of suramin. Biochemistry 2006; 45: 899-906.
24. Pesenti E, Sola F, Mongelli N, Grandi M, Spreafico F. Suramin prevents neovascularization and tumor growth through blocking of basic fibroblast growth factor activity. Br J Cancer 1992; 66: 367-72.
25. Gagliardi AH, AH; Collins DC. Inhibition of angiogenesis by suramin. Cancer Res 1992; 52: 5073-5.
26. Palamakumbura AH, Sommer P, Trackman PC. Autocrine growth factor regulation of lysyl oxidase expression in transformed fibroblasts. J Biol Chem 2003; 278: 30781-7.
27. Murakami MT, Gava LM, Zela SP, et al. Crystallization and preliminary xray diffraction analysis of suramin, a highly charged polysulfonated naphthylurea, complexed with a myotoxic PLA2 from Bothrops asper venom. Biophys Acta 2004; 1703: 83-5.
28. Middaugh CR, Mach H, Burke CJ, et al. Nature of the interaction of growth factors with suramin. Biochemistry 1992; 31: 9016-24.
29. Zamai MP, AH, Grandi M, Mongeli N, Caiolfa VR. Antiangiogenic naphthalene sulfonic distamycin-A derivatives tightly interact with human basic fibroblast growth factor. Med Chem Res 1997; 7: 36-44.
30. Larsen AK, Escargueil AE, Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 2003; 99: 167-81.
31. Marchetti D, Reiland J, Erwin B, Roy M. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues. Int J Cancer 2003; 104: 167-74.
32. He JB, Yi GZ, Yang K, Xiang Z, Xie MF, Zhang P. Inhibitory effects of suramin on growth of transplanted lung adencarcinoma in mice and its mechanisms. Ai Zheng 2008; 27: 359-63.
33. Ullmann H, Meis S, Hongwiset D. Synthesis and structureactivity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency. J Med Chem 2005; 48: 7040-8.
34. Ganesh VK, Muthuvel SK, Smith SA, Kotwal GJ, Murthy KH. Structural basis for antagonism by suramin of heparin binding to vaccinia complement protein. Biochemistry, 2005; 44: 10757-65.
35. Fleck SL, Birdsall B, Babon J, et al. Suramin and suramin analogues inhibit merozoite surface protein-1 secondary [rocessing and erythrocyte invasion by the malaria parasite Plasmodium falciparum. J Biol Chem 2003; 278: 47670-7.
36. Petcu DJ, Aldrich CE, Coates L, Taylor JM, Mason WS. Suramin inhibits in vitro infection by duck hepatitis B virus, Rous sarcoma virus, and hepatitis delta virus. Virology 1988; 167: 385-92.
37. Taylor JM, Han Z. Purinergic receptor functionality is necessary for infection of human hepatocytes by hepatitis delta virus and hepatitis B virus. PLoS One 2010; 5: e15784.
38. Zhuang S, Lu B, Daubert RA, Chavin KD, Wang L, Schnellmann RG. Suramin promotes recovery from renal ischemia/reperfusion injury in mice. Kidney Int 2009; 75: 304-11.
39. Goto T, Takeuchi S, Miura K, et al. Suramin prevents fulminant hepatic failure resulting in reduction of lethality through the suppression of NF-kappaB activity. Cytokine 2006; 33: 28-35.
40. Kharlamov A, Jones SC, Kim DK. Suramin reduces infarct volume in a model of focal brain ischemia in rats. Exp Brain Res 2002; 147: 353-9.
41. Li Y, Huard J. Differentiation of muscle-derived cells into myofibroblasts in injured skeletal muscle. Am J Pathol 2002; 161: 895-907.
42. Schrier RW, Wang W, Poole B, Mitra A. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 2004; 114: 5-14.
43. Zhuang S, Schnellmann RG. Suramin promotes proliferation and scattering of renal epithelial cells. J Pharmacol Exp Ther 2005; 314: 383-90.
44. Eichhorst ST, Krueger A, Müerköster S, et al. Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice. Nat Med 2004; 10: 602-9.
45. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115.
46. Li C, Jiang X, Yang L, Liu X, Yue S, Li L. Involvement of sphingosine 1-phosphate (SIP)/S1P3 signaling in cholestasis-induced liver fibrosis. Am J Pathol 2009; 175: 1464-72.
47. Dranoff JA, Kruglov EA, Abreu-Lanfranco O, Nguyen T, Arora G, Jain D. Prevention of liver fibrosis by the purinoceptor antagonist pyridoxal-phosphate-6-azophenyl-2', 4'-disulfonate (PPADS). In Vivo 2007; 21: 957-65.
48. Shiono T, Kodama M, Hanawa H, Fuse K, Yamamoto T, Aizawa Y. Suppression of myocardial inflammation using suramin, a growth factor blocker. Circ J 2002; 66: 385-9.
49. Urasawa K, Kaneta S, Nakano N, et al. Vascular smooth muscle cell proliferation is effectively suppressed by the non-specific growth factor inhibitor suramin. Jpn Heart J 2001; 42: 221-33.
50. Di Prospero NA, Zhou XR, Meiners S, McAuliffe WG, Ho SY, Geller HM. Suramin disrupts the gliotic response following a stab wound injury to the adult rat brain. J Neurocytol 1998; 27: 491-506.
51. Chan YS, Li Y, Foster W, et al. Antifibrotic effects of suramin in injured skeletal muscle after laceration. J Appl Physiol 2003; 95: 771-80.
52. Nozaki M, Li Y, Zhu J, et al. Improved muscle healing after contusion injury by the inhibitory effect of suramin on myostatin, a negative regulator of muscle growth. Am J Sports Med 2008; 36: 2354-62.
53. Zumkeller W, Schofield PN. Growth factors, cytokinesand soluble forms of receptor molecules in cancer patients. Anticancer Res 1995; 15: 343-8.
54. Mietz H, Chévez-Barrios P, Lieberman MW. A mouse model to study the wound healing response following filtration surgery. Graefes Arch Clin Exp Ophthalmol 1998; 236: 467-75.
55. Mietz H, Chévez-Barrios P, Feldman RM, Lieberman MW. Suramin inhibits wound healing following filtering procedures for glaucoma. Br J Ophthalmon 1998; 82: 816-20.
56. Mietz H, Krieglstein GK. Suramin to enhance glaucoma filtering procedures: A clinical comparison with mitomycin. Ophthalmic Surg Lasers 2001; 32: 358-69.
57. Akman A, Bilezikçi B, Küçükerdönmez C, Demirhan B, Aydin P. Suramin modulates wound healing of rabbit conjunctiva after trabeculectomy: comparison with mitomycin C. Curr Eye Res 2003; 26: 37-43.
58. Gutteridge WE. Existing chemotherapy and its limitations. Br Med Bull 1985; 41: 162-8.
59. Müller WE WU. Biochim Biophys Acta 1976; 427.
60. Vansterkenburg EL, Wilting J, Janssen LH. Influence of pH on the binding of suramin to human serum albumin. Biochem Pharmacol 1989; 38: 3029-35.
61. Bos OJ, Vansterkenburg EL, Boon JP, Fischer MJ, Wilting J, Janssen LH. Location and characterization of the suramin binding sites of human serum albumin. Biochem Pharmacol 1990; 40: 1595-9.
62. Fairlamb AH, Bowman IB. Cell disruption and subcellular fractionation of Trypanosoma brucei. Trans R Soc Trop Med Hyg 1974; 68: 275.
63. Collins JM, Klecker RW Jr, Yarchoan R, et al. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol 1986; 26: 22-6.
64. Hawking F. Suramin: with special reference to onchocerciasis. Adv Pharmacol Chemother 1978; 15: 289-322.
65. Apted FI. Present status of chemotherapy and chemopropylaxis of human trypanosomiasis in the Eastern Hemisphere. Pharmacol Ther 1980; 11: 391-413.
66. Sridhara R, Eisenberger MA, Sinibaldi VJ, Reyno LM, Egorin MJ. Evaluation of biomarkers of survival response in hormonerefractory prostate cancer patients treated with suramin. Proc Am Soc ClinOncol 1998; 7: 631-4.
67. Lu Z, Wientjes TS, Au JL. Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors. Pharm Res 2005; 22: 1069-78.
68. Song S, Yu B, Wei Y, Wientjes MG, Au JL. Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxelpretreated human breast xenograft tumors. Clin Cancer Res 2004; 15: 6058-65.
69. Villalona-Calero MA, Wientjes MG, Otterson GA, et al. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. Clin Cancer Res 2003; 15: 3303-11.
70. Villalona-Calero MA, Otterson GA, Wientjes MG, et al. Noncytotoxic suramin as a chemosensitizer in patients with advanced nonsmall-cell lung cancer: a phase II study. Ann Oncol 2008; 19: 1903-9.